



QP-Prostate®



QP-Prostate®

Streamline your fusion biopsy
and focal therapy procedures
through the power of AI

Discover QP-Prostate®

Prostate cancer ranks as the second most prevalent cancer in men, posing a significant public health concern.

Accurate identification and localization of lesions is critical for precise biopsies and successful focal therapy. However, the lack of standardized reporting can hinder communication between radiologist and urologist, and complex integration with fusion biopsy and focal therapy systems make workflows time-consuming.

Introducing QP-Prostate®, an AI-powered solution that streamlines urologists' workflows. By identifying suspicious lesions, generating structured reports, and integrating seamlessly into fusion biopsy and focal therapy systems, QP-Prostate® empowers urologists by saving time, enabling better-informed decisions, reducing the number of unnecessary biopsies, and delivering more precise care.



The new prostate ecosystem platform



AI POWERED USER INTERFACE

- Advanced viewing with 3D visualization
- Structured report enhances clinical communication


SEAMLESS INTEGRATION

Seamless integration into PACS and fusion biopsy systems.

DynaCAD  KOELIS FUJIFILM


Canon UC-CARE EXACT IMAGING  esaote
HEALTH WITH CARE

QP-Prostate[®], a suite of enhanced diagnostic capabilities




END-TO-END PROSTATE MANAGEMENT WORKFLOW

Seamless integration into PACS, fusion biopsy and focal therapy systems allowing a fully automated workflow.




AUTOMATIC PROSTATE SEGMENTATION

Automatically segments each prostate region, including the peripheral zone, the transitional and central zone, and the seminal vesicles.




AUTOMATED LESION DETECTION & DIAGNOSIS

QP-Prostate[®] automatically identifies and highlights prostate regions suspicious for aggressive prostate cancer, assigning each a confidence-based classification score.



FUSION BIOPSY PLANNING

QP-Prostate[®] is fully integrated into most of the fusion biopsy devices, to allow a more accurate targeted biopsy.



FOCAL THERAPY

QP-Prostate[®] helps planning focal therapy treatment through an accurate and editable 3D visualization.

QP-Prostate® in action

Clinical Case 01



74 YO BIOPSY PATIENT WITH PSA: 15 NG/ML.

THE RADIOLOGIST DETECTS 1 LESION:


- L1 in the middle gland peripheral zone, posteromedial/lateral area (PI-RADS 4).

QP-PROSTATE® DETECTS 1 LESION:

- L1 No lesion.
- L2 Suspicious lesion.

TARGETED BIOPSY CONFIRMS 1 LESION:

- L1 Benign prostatic tissue.
- L2 Gleason score 4+3.



Clinical Case 02



72 YO - PSA: 6.3 NG/ML. DPSA: 0.12 WITHOUT

QP-PROSTATE® PI-RADS 2.

2023: THE RADIOLOGIST DETECTS NO LESIONS:
(Does not have QP-Prostate®).

73 YO - PSA: 7.39 NG/ML. DPSA: 0.13 WITH

QP-PROSTATE® PI-RADS 4.

2024: THE RADIOLOGIST DETECTS 1 LESION:

- L1 suspicious lesion in the left TZ. (PIRADS 4).

QP-PROSTATE® DETECTS 1 LESION:

- L1 Highly suspicious.

TARGETED BIOPSY CONFIRMED 1 LESION:

- L1 Gleason score 3+4.

Retrospectively QP-Prostate® analyzes the 2023 study, identifying the suspicious lesion; not identified in the previous reading.

